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AW464 (NSC 706704) is a novel benzothiazole substituted quinol compound active against colon, renal and certain breast cancer
cell lines. NCI COMPARE analysis indicates possible interaction with thioredoxin/thioredoxin reductase, which is upregulated under
hypoxia. Through activity on HIF1a, VEGF levels are regulated and angiogenesis controlled. A thioredoxin inhibitor could therefore
exhibit enhanced hypoxic toxicity and indirect antiangiogenic effects. In vitro experiments were performed on colorectal and breast
cancer cell lines under both normoxic and hypoxic conditions and results compared against those obtained with normal cell lines,
fibroblasts and keratinocytes. Antiangiogenic effects were studied using both large and microvessel cells. Indirect antiangiogenic effects
(production of angiogenic growth factors) were studied via ELISA. We show that AW464 exerts antiproliferative effects on tumour
cell lines as well as endothelial cells with an IC50 of B0.5mM. Fibroblasts are however resistant. Proliferating, rather than quiescent,
endothelial cells are sensitive to the drug indicating potential antiangiogenic rather than antivascular action. Endothelial differentiation
is also inhibited in vitro. Hypoxia (1% O2 for 48h) sensitises colorectal cells to lower drug concentrations, and in HT29s greater
inhibition of VEGF is observed under such conditions. In contrast, bFGF levels are unaffected, suggesting possible involvement of
HIF1a. Thus, AW464 is a promising chemotherapeutic drug that may have enhanced potency under hypoxic conditions and also
additional antiangiogenic activity.
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Colorectal cancer is the fourth most common cancer in the world.
Surgery is the mainstay of treatment of this tumour with
chemotherapy being used in the adjuvant and palliative setting.
5-Fluorouracil remains the cornerstone of chemotherapy for
colorectal cancer.
Angiogenesis, the growth of new blood vessels from pre-existing
ones, is essential for the development of tumours (Folkman, 1990)
as well as for invasion and metastasis. So an agent with both
antitumour and antiangiogenic activity would be useful for
colorectal cancer therapy.
AW464 (NSC 706704) is a novel benzothiazole substituted
quinol compound with selective activity concentrated in certain
colon (HCT116 and HT29), renal (CAKI-1 and ACHN) and breast
cancer cell lines (MCF7, MDA-N and MDA-MB435) on the NCI
panel (Wells et al, 2003). COMPARE analysis indicates possible
interaction with thioredoxin/thioredoxin reductase signalling. The
proposed molecular target of AW464, thioredoxin, belongs to a
family of small 12kDa redox proteins that undergo NADPH
dependent reduction by the enzyme thioredoxin reductase and in
turn reduces oxidised cysteine group on proteins (reviewed by
Powis and Montfort, 2001; Hirota et al, 2002). AW464 has been
proposed to crosslink irreversibly to cysteine residues 32 and 35 of
the thioredoxin active site via its two b-carbon atoms; the first link
is reversible, whereas the second crosslink is thought to be
irreversible.
The effects of thioredoxin in the cell are pleiotropic, viz
increasing cell proliferation through ribonucleotide reductase
(Mau and Powis, 1992), prevention of apoptosis by inhibiting
ASK-1 (Saitoh et al, 1998) and protection against oxidative stress
through the activity of thioredoxin peroxidases (Powis and
Montfort, 2001). Therefore, inhibition of thioredoxin can have
antiproliferative and proapoptotic effects (Pallis et al, 2003).
Thioredoxin is upregulated in a wide variety of tumours such as
mesothelioma (Kahlos et al, 2001), leukaemia (Shao et al, 2001),
lung (Kakolyris et al, 2001), hepatocellular (Miyazaki et al, 1998)
and renal cancer (Lichtenfels et al, 2003). Colorectal cancer tissues
have also been shown to overexpress thioredoxin and hence
thioredoxin could be an important therapeutic target for colon
cancer (Raffel et al, 2003). Preliminary immunohistochemical
studies suggested that in normal human colon thioredoxin is
found in the dividing crypt cells, while in colorectal cancer
thioredoxin is overexpressed in cancer cells (Powis et al, 1998).
Thioredoxin has also been reported to be upregulated during
hypoxia (Berggren et al, 1996) and this, we hypothesise, may lead
to increased AW464 efficacy under hypoxic conditions. Through
its activity on HIF1a, thioredoxin can also regulate VEGF levels
and hence angiogenesis (Welsh et al, 2002). A thioredoxin
inhibitor such as AW464 may thus have both direct and indirect
antiangiogenic effects and enhanced hypoxic toxicity.
This study aimed at studying the in vitro effects of AW464 on
colorectal cancer and on angiogenesis.
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sMATERIALS AND METHODS
HUVEC isolation
Human umbilical vein endothelial cells (HUVEC) were isolated
from umbilical cords obtained from the Department of Obstetrics,
City Hospital, Nottingham, by the collagenase perfusion technique
(Jaffe et al, 1973). Briefly, the umbilical vein was cannulated and
5ml of prewarmed type 1 Collagenase (Lorne Laboratories,
Twyford, UK) was infused through it. The free end of the cord
was clamped and then incubated at 371C in a 5% CO2
environment. The vein was flushed with 20ml of HUVEC medium
and the isolated endothelial cells centrifuged at 1500r.p.m. for
5min. The supernatant was aspirated and the pellet resuspended in
5ml of HUVEC medium and plated on a pregelatinised tissue
culture flask (Sarstedt, UK). Cells isolated from at least two
umbilical cords were pooled for further culture. Cells for
experiments were used between passage 2 and 6.
Tumour and normal cells
The colorectal cancer cell lines HT29, SW480, SW620 and the
breast cancer cell line MCF7 (American Type Culture Collection)
were chosen for this study. SW620 and SW480 form a matched pair
of primary and metastatic population of cells from the same
patient.
Several normal cell types, in addition to HUVEC, were used for
comparison. These include MRCV lung fibroblasts (ECACC),
NHDF (normal human dermal fibroblasts), NHEK (neonatal
human epidermal keratinocytes) pooled (Cambrex, UK) and
HUMMEC (human mammary microvessel endothelial cells) (a gift
from Dr C Murray, University of Nottingham).
HT29 cells were used between passage 140 and 150, SW480
between 110 and 120, SW620 between 100 and 110, MCF7 between
passage 20 and 30, MRCV between 22 and 26, NHDF between 3 and
8 and NHEK between 1 and 10. HT29 cells were grown in McCoy’s
5a medium, SW620 and SW480 in L-15 medium and MCF7 in
RPMI 1640 medium. All media were supplemented with 10% Fe-
supplemented donor calf serum (PAA Laboratories, Somerset,
UK), 1% penicillin–streptomycin (Sigma, Dorset, UK) and 1% L-
glutamine (Sigma). MEM medium for growth of MRCV fibroblasts
was additionally supplemented with 1% HEPES buffer (Sigma), 1%
nonessential amino acids (Sigma) and 1% sodium bicarbonate
(Sigma). NHDF fibroblasts and NHEK keratinocytes were grown in
FGM-2 bullet-kit medium (Cambrex) and KGM bullet-kit
medium (Cambrex), respectively. HUVEC and HUMMEC were
grown in a 1:1 mix of Hams F12 medium (Sigma) and Medium
199 (Sigma), sterile water (Baxter, UK) supplemented with 20% Fe
supplemented donor calf serum (PAA laboratories, UK), 1%
HEPES solution, 1% sodium bicarbonate, 1% penicillin–strepto-
mycin, 1% L-glutamine, 15000U of Heparin (CP Pharmaceuticals
Limited, Wrexham, UK), 20ngml
1 bFGF and 5ngml
1 EGF
(Peprotech, UK). All media were stored at 41C for no more than 1
month.
Assays
MTS assay Cells were plated on flat-bottomed 96-well plates
(Nucleon, Riskily, Denmark) in a volume of 180ml of the respective
culture medium at an appropriate seeding density for each cell line
to ensure that cells were still in the exponential phase of growth at
the end of the incubation period. These were 1000cells per well for
MCF7, HT29, HUVEC, HUMMEC, MRCV and NHDF and
5000cells per well for SW620, SW480 and NHEK. For HUVEC,
the 96-well plates were pregelatinised with 0.2% gelatin in PBS.
After 24h incubation, 20mlo f1 0 drug concentration were added
to a triplicate of wells to achieve the drug concentration in a final
volume of 200ml. In total, 20ml of medium only or vehicle only
(DMSO) were added to controls. After 72h of incubation, 40mlo f
MTS-PES reagent (Promega, Southampton, UK) were added to
each well and incubated for a further 3h for colour development.
The incubation time was prolonged to 96h for SW620 and 120h
for SW480 to ensure at least one doubling of absorbance. The time
for development of formazan was also increased for these cell lines
to 4h instead of 3h. The absorbance was read from the plates at
492nm on a plate reader. Absorbance levels from drug treated cells
and untreated controls were corrected against medium only blank
controls. The mean absorbance of drug treated wells was expressed
as a percentage of nontreated controls to calculate the percentage
proliferation status (Carmichael et al, 1987).
Growth assays Proliferation status of cells was also assessed by
simple counting of cell number after treatment with drugs
(Saunders et al, 1997). In total, 10
5 cells of each cell line were
plated out on six-well tissue culture plates (Corning, High
Wycombe, UK) in a volume of 3ml of media. The cells were
allowed to attach overnight, and then exposed to drugs for 24, 48
and 72h. A pair of wells were washed with PBS, trypsinised and
counted before drug treatment to give the number of cells before
the addition of drug. This was taken as the 0h time point. Further
readings were conducted at 24, 48 and 72h after the addition of
drug. Effects were also compared with drug treatment for 48h of
incubation under normoxic and hypoxic conditions. Hypoxia was
achieved in a water-jacketed Thermoforma incubator gassed with
nitrogen to achieve 1% O2.
The effect of the drug on quiescent as opposed to proliferating
endothelium were assessed by seeding HUVEC and HUMMEC in
six-well plates at a density of 210
5cellswell
1 and generating a
growth curve. When cell numbers reached a plateau, media was
aspirated off and replaced with either fresh media for controls or
different drug dilutions of AW464 and treated for a further 24, 48
and 72h.
Cell survival assays While the MTS assay and the growth kinetic
assays measure cell proliferation, cell survival assays measure
reproductive integrity. These assays were performed according to
the protocol of Liebmann et al (1993) with some modifications.
Petri dishes (100mm) (Corning, High Wycombe, UK) were plated
with 510
5cells in 10ml of media or 60-mm Petri dishes were
plated with 1.810
5cells in 3.5ml of media. The cells were allowed
to attach for 24h. Media was aspirated off and the exponentially
growing cells were then exposed to drug for 72h, following which
they were trypsinised and plated out for colony formation.
Incubation time was 4 weeks for all tumour cell lines except
SW620 (3 weeks), 2 weeks for fibroblasts and 10 days for HUVEC.
Finally, colonies were fixed with methanol (Fisher Scientific,
Loughborough, UK) and stained with 1% crystal violet (Sigma)
vide a protocol modified from Freshney (1994). Colonies were
counted by eye and confirmation by microscopy carried out as
necessary. Any cluster of cells greater than 50 in number was
counted as a colony. All survival points were in triplicate and
experiments repeated at least twice.
Tube formation studies on Matrigel The method was adapted
from Dicker et al (2001). Petri dishes (100mm) were plated with
510
5 HUVEC cells in 6ml of media. The cells were allowed to
attach for 24h. The media was aspirated off and exponentially
growing cells were then exposed to 6ml of the IC50 dose of control
drugs paclitaxel, fumagillin and AW464 for 72h. For each drug
treated condition or control, 50000cells in 200ml of media were
then added to wells of a 24-well plate precoated with Matrigel at
room temperature, for 1h. Cells were then incubated at 371C and
5% CO2 for 48h. Photographs were taken for assessment of tube
formation on Matrigel at 24h postplating.
Indirect antiangiogenic effects Indirect antiangiogenic effects of
AW464 were estimated by effects on the production of angiogenic
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sgrowth factors by tumour cell lines. Cells were plated onto six-well
plates at a density of 110
5cells for untreated controls and
210
5cells for drug treated conditions. After attachment over-
night, media was aspirated off and 3ml of different AW464
dilutions or media only were added to the wells. The cells were
incubated for a total of 72h. For the last 24 or 48h of the
incubation period, cells were exposed either to normoxic or
hypoxic (1% O2) conditions. The supernatant was centrifuged at
2000r.p.m. for 5min to remove debris, aliquoted out and stored at
801C until further use. ELISAs for VEGF and bFGF were
conducted according to R&D systems duo-set protocols (Ishibashi
et al, 2001). Plates were read on a plate reader at 405nm. VEGF
and bFGF production per cell was calculated from the standard
curves obtained.
Statistical analysis
A Student’s t-test was used to calculate probability values and
Po0.05 was considered to be statistically significant (indicated by
* on graphs).
RESULTS
Cytotoxic effect of AW464 on tumour and endothelial cells
Both MTS assays (Figure 1) and growth curve experiments
(Figure 2) with AW464 demonstrate that the drug inhibits cell
proliferation for all tumour cell lines (HT29, SW480, SW620 and
MCF7) as well as endothelial cells (HUVEC). The maximum
antiproliferative effect is evident after 72h drug incubation. The
IC50 (50% growth inhibitory concentration) lies between 0.1 and
1mM. Cell survival assays, conducted subsequently at the IC50 dose
(0.5mM), showed a decrease in clonogenic survival indicating a
cytotoxic rather than cytostatic mechanism of action. This profile
of action of AW464 was quite similar to the control drug paclitaxel,
which also showed a cytotoxic effect on all tumour cell lines as well
as endothelial cells (data not shown). MRCV fibroblasts, however,
exhibited a relative resistance to the drug (Figure 3). This
differential sensitivity was further explored in later experiments
(see later).
AW464 inhibits endothelial tube differentiation
Angiogenesis is a stepwise process where endothelial cells must
differentiate into tubes to form new vessels. The effects of the
drugs were therefore assessed not only on the proliferation of
endothelial cells but also on the ability to differentiate into tubes
on a basement membrane matrix, Matrigel. Matrigel is a
solubilised basement membrane preparation extracted from the
Engelbreth-Holm-Swarm mouse sarcoma. Its major components
are laminin, collagen IV and heparan sulphate proteoglycans.
HUVEC differentiate into capillary like structures on Matrigel in
the presence of serum and growth factors. The formation of tube
like vessels on Matrigel can therefore be used to assess compounds
that either stimulate or inhibit angiogenesis (Ponce, 2001). AW464
inhibited endothelial differentiation at the IC50 dose as evident
from tubal abortion at both 24 and 48h postplating (data not
shown). The effects were comparable to the control drugs,
paclitaxel and fumagillin.
Fibroblasts are relatively resistant to AW464
The effect of AW464 on the proliferation of different normal cell
lines was investigated using the MTS assay (Figure 4). Both large
(HUVEC) and microvessel (HUMMEC) endothelial cells and
keratinocytes (NHEK) were as sensitive as the tumour lines to
the drug with an IC50 of B0.5mM. Fibroblasts (NHDF and MRCV)
were relatively resistant to the IC50 dose (Figure 4A). As the
drug dose increases to 1mM, the MRCV cells become sensitive
to the drug but the differential with NHDFs still applies as
they are resistant in comparison to the other cell lines (Po0.05)
(Figure 4B).
AW464 may be more effective under hypoxic conditions
As thioredoxin and thioredoxin reductase have been shown to be
upregulated under hypoxic conditions (Berggren et al, 1996), we
investigated whether a potential thioredoxin inhibitor such as
AW464 could be more effective under hypoxic conditions. On 48h
of exposure to hypoxia, lower doses of AW464 (0.1–0.001mM)
that had very little effect under normoxic conditions, were effective
in decreasing proliferation (Figure 5A–C). There was approxi-
mately a five-fold reduction in the IC50 (to B0.1mM) for all the
colorectal cancer cell lines under hypoxic conditions. These results
indicate that AW464 may be more effective under hypoxic
conditions.
Quiescent endothelial cells are resistant to AW464
Antiangiogenic agents should be effective only against proliferat-
ing endothelial cells in contrast to antivascular agents that cause
vascular shutdown. In order to investigate whether the effect of
AW464 on endothelial cells was antiangiogenic, we considered the
effects of AW464 on quiescent as opposed to proliferating
endothelial cells (Figure 6A(a, b)). AW464 was effective against
proliferating large (HUVEC) and microvessel (HUMMEC) en-
dothelial cells but quiescent cells were resistant to the drug over
the whole dose range (0.1–1mM) after 24, 48 and 72h of exposure
(Figure 6B(a, b)). Thus, the mechanism of action of the drug on
endothelial cells is potentially antiangiogenic rather than anti-
vascular, although confirmation by in vivo experimentation is
required.
Indirect antiangiogenic effects of AW464
Angiogenesis may depend on growth factor production from
tumour cells to stimulate the endothelial cells via a paracrine loop.
The effect of AW464 on growth factor production was investigated
under both normoxic and hypoxic conditions. Low doses of the
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Figure 1 MTS assay results: percentage absorbance as compared to
controls after 72h of treatment with AW464 for HT29 (K), SW480 (n),
SW620 ( ), MCF7 ( ) and HUVEC (*) cell lines. Data points were in
triplicate in individual experiments and error bars represent standard error
of means.
In vitro characterisation of AW464
A Mukherjee et al
352
British Journal of Cancer (2005) 92(2), 350–358 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sdrug (oIC50) cause a decrease in VEGF production (Figure 7A, B).
VEGF was upregulated under hypoxic conditions in colorectal cell
lines but not by a significant amount. The relative decrease in
VEGF levels following AW464 treatment was greater under
hypoxic than under normoxic conditions in the HT29 cell line
(Figure 7A, B). In contrast, none of the tumour cell lines produced
bFGF under normoxic or hypoxic conditions and AW464 had no
effects on basal levels (not shown). Since VEGF, unlike bFGF, is
under the regulation of HIF1a, such results suggest that HIF1a may
be potentially affected by the drug.
DISCUSSION
Chemotherapy for colorectal cancer is predominantly used in the
adjuvant setting for advanced and metastatic disease. 5-Flourour-
acil and in recent years, irinotecan, have been the two commonly
used drugs for treating this cancer. Unfortunately, median survival
for advanced disease is still poor (14.8–17.4 months) (Berlin,
2002). Dukes’ staging remains the most important prognostic
factor for colorectal cancer. In the search for new targets for
prognosis and survival, several studies have focused on angiogen-
esis. Some have indicated a positive correlation between angiogen-
esis and prognosis of colorectal cancer (Frank et al, 1995;
Pantalone et al, 1999), while others have failed to be conclusive
(Bossi et al, 1995; Lee et al, 2000). Among other molecules,
thioredoxin has also been shown to be an important prognostic
factor for colorectal cancer (Raffel et al, 2003) and involved with
colorectal carcinogenesis (Berggren et al, 1996, Lechner et al,
2002). Thioredoxin/thioredoxin reductase signalling therefore may
be a novel pathway to target in this malignancy. Thioredoxin and
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Figure 2 Temporal plots showing action of IC50 AW464 (K) and untreated controls (E) on SW480 (A), SW620 (B), HT29 (C), MCF7 (D), HUVEC
(E) and HUMMEC (F) at 24, 48 and 72h time points. % growth compared to 0h time point (time of drug addition) was plotted in duplicate and error bars
represent standard deviation.
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Figure 3 Mean clonogenic cell survival of cells treated with IC50 AW464.
Data pooled from two experiments with error bars representing standard
error of means. Plating efficiencies of individual cell lines with standard error
were as follows: MCF7 – 5575%; SW480 – 2075%; SW620 – 40713%;
HT29 – 1170.3%; HUVEC – 2272%; MRCV – 3171%.
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sthioredoxin reductase are also important proteins present in
endothelial cells to tackle oxidative stress (Fernando et al, 1992;
Anema et al, 1999). So a putative thioredoxin inhibitor may have
potential antiangiogenic activity.
The novel drug, AW464, on COMPARE analysis and database
mining, was thought to be involved in thioredoxin/thioredoxin
reductase signalling. On microarray analysis at the NCI, after
treatment of HCT116 cells with 1mM AW464 for 24h, the only gene
found to be upregulated was thioredoxin reductase (Westwell et al,
2003).
In our study, the drug was found to inhibit cell proliferation in
colorectal and breast tumour cell lines as well as HUVEC with an
IC50 of B0.5mM. The antiproliferative effect of a thioredoxin
inhibitor may be attributed to the decrease in transfer of reducing
equivalents to ribonucleotide reductase from active thioredoxin,
leading to decreased DNA synthesis. The effect of the drug at the
IC50 dose was cytotoxic rather than cytostatic as evident by a
decrease in clonogenic survival. In contrast, the proliferation and
clonogenic survival of fibroblasts MRCV was unaffected. This led
to investigations for relative sensitivities of different cell lines.
Both large, HUVEC and microvessel endothelial cells, HUMMEC
were found to be as sensitive to the drug as tumour cells.
Thioredoxin and thioredoxin reductase have been identified as
major redox proteins in HUVEC (Fernando et al, 1992; Anema
et al, 1999) and therefore inhibition of thioredoxin should have
direct antiproliferative effects. This was corroborated by this study.
The sensitivity of microvessel endothelial cells, HUMMEC, was
important as angiogenesis involves the proliferation of microvessel
endothelial cells. Inorganic arsenic, another compound that can
target the thioredoxin system, has also been shown to be toxic to
rat heart microvessel endothelial cells in its trivalent form (Hirano
et al, 2003) and inhibits endothelial cell proliferation in vitro and
angiogenesis in vivo (Don et al, 2003). Both fibroblast cell lines,
NHDF and MRCV, are resistant to the IC50 dose of AW464. With
an increase in dose to 1mM, fibroblasts also become sensitive to
AW464; but in comparison to other cell lines dermal fibroblasts
are still relatively resistant. Epidermal keratinocytes, on the other
hand, are sensitive. The relative resistance of the fibroblasts cannot
be explained by proliferation differences alone and some under-
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Figure 4 MTS assay results: percentage proliferation as compared to
controls after 72h of treatment with 0.5mM (IC50)( A) and 1mM (B)
AW464. Data points were in triplicate in individual experiments and error
bars represent standard error of means.
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Figure 5 Effects of AW464 on SW620 (A), SW480 (B) and HT29 (C)
under normoxia (K) and hypoxia (1% O2)( &) for 48h compared by
growth assays. Results were normalised to respective controls with
standard deviation depicted as error bars. Mean control cell numbers
(10
4cells) were as follows: SW 620: 31.25 (normoxia); 19.75 (hypoxia);
SW480: 37.25 (normoxia); 23 (hypoxia); HT29: 19.87 (normoxia); 17.37
(hypoxia).
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slying factor such as differential thioredoxin levels may explain this
phenomenon and warrants further investigation. For example, it is
known that high levels of thioredoxin are present in epidermal
keratinocytes to protect against UV-B-induced skin injury
(Schallreuter and Wood, 2001), and this may explain the sensitivity
of keratinocytes to AW464. Differential sensitivity assays in vitro
may be a pointer of drug toxicities in vivo. Dermal reactions may
therefore be predicted as a toxicity of the drug. Since pulmonary
fibroblasts MRCV are relatively resistant, lung toxicities may
potentially be minimised.
An antiangiogenic agent should be active only against prolifer-
ating and not quiescent endothelial cells, in contrast to anti-
vascular agents. AW464 was found to affect only proliferating
endothelial cells, whereas quiescent cells were resistant. The
mechanism of action on endothelial cells is thus potentially
antiangiogenic rather than antivascular. In addition to there being
little effect on normal vasculature there may be significant
therapeutic implications in that AW464 may have to be
administered chronically or in combination with other agents
rather than it being used acutely if it were a tumour vascular
targeting agent. Further in vivo characterisation is required to
confirm whether the drug is a pure antiangiogenic agent or
whether it exhibits any antivascular action.
Another therapeutic problem common in tumours is the
hypoxic cells at the core that are often resistant to traditional
modes of therapy. Thioredoxin expression however is increased
under hypoxic conditions (Berggren et al, 1996) and hence a
thioredoxin inhibitor, we hypothesised, could be more effective
under hypoxic conditions. The increased antiproliferative effect of
lower doses of AW464 observed under hypoxia may ensure better
eradication of the hypoxic population of cells. A low-dose AW464
strategy may thus be combined with radiation or other
chemotherapeutic agents that target the oxic cells for greater
therapeutic efficacy.
The hypoxic upregulation of thioredoxin also has indirect effects
on angiogenesis. Thioredoxin transfection has been shown to
increase HIF1a transactivation activity and the protein products of
hypoxia-responsive genes such as VEGF and nitric-oxide synthase
in MCF7 breast and HT29 colon cancer cell lines under both
aerobic and hypoxic conditions (Welsh et al, 2002). In the current
study, low doses of AW464 (oIC50) were found to inhibit the
production of VEGF and such inhibition was greater under
hypoxic conditions. Thioredoxin is known to be upregulated under
hypoxia and transfers reducing equivalents to the dual function
DNA repair endonuclease Ref1 and thence to HIF1a (Ema et al,
1999). It then dimerises with HIF1b to activate downstream factors
such as VEGF. Thus, a thioredoxin inhibitor such as AW464 may
stop the transfer of sulphhydryl moieties to HIF1a and thereby
downregulate VEGF more effectively, as seen in this study, under
hypoxic conditions. The colorectal cancer cell lines in this study
produced low levels of angiogenic growth factors. AW464 was
efficacious in lowering these levels even further, and this indicates
that the effect of the drug may be more marked for cell lines that
produce high levels of endogenous growth factors. In contrast,
bFGF levels were unaffected by the drug or hypoxia. Unlike the
HIF1a-VEGF signalling pathway, hypoxia induced bFGF expres-
sion is mediated through the JNK signal transduction pathway (Le
and Corry, 1999). This differential regulation is an indicator that
HIF1a may be affected by AW464 and experiments are currently
underway to examine this. PX-12 (a thioredoxin inhibitor) (Welsh
et al, 2003a), and pleurotin and PX478 (thioredoxin reductase
inhibitors) (Powis et al, 2003; Welsh et al, 2003b, 2004) have
already been characterised as inhibitors of HIF1a. However, these
thioredoxin inhibitors target the Cys73 of thioredoxin unlike
AW464 that is postulated to target Cys 32 and 35.
The decrease in VEGF production at low doses of AW464
(oIC50) under normoxic conditions could probably be explained
due to the fact that there are also normoxic pathways regulating
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Figure 6 (A) (a) HUVEC and HUMMEC (b) were grown to quiescence as indicated by cell numbers on the growth curves. (B) At this time-point
(arrow), HUVEC (a) and HUMMEC (b) were exposed to different doses of AW464 (no drug control; 0.1; 0.5; 1mM) and cell numbers were assessed 24, 48
and 72h later. Readings are from one representative experiment and error bars represent standard deviation.
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Chun et al, 2002). Thioredoxin has been shown to regulate this
pathway by inhibiting PTEN, which in turn is a negative regulator
of the PI3K pathway (Meuillet et al, 2004). Hence, thioredoxin
inhibitors such as AW464 might indirectly impact on angiogenesis
through pathways affecting HIF1a under normoxic and hypoxic
conditions. The increase in VEGF production at higher doses of
AW464 probably represents a stress response, as high doses of
chemotherapy have been known to induce VEGF production. In
clinical trials with VEGF receptor tyrosine kinase inhibitors, VEGF
serum levels increased in patients treated by high doses (Drevs,
2003). Also, heat shock proteins, hsp70 and hsp105, have been
shown to be induced at high doses of AW464 in NCI microarrays.
Heat shock proteins stabilise HIF1 by preventing its degradation
(Zhou et al, 2004) and may be involved in this stress response. It
should however be borne in mind that the regulation of VEGF
expression is quite complex, occurring at transcriptional, post-
transcriptional and translational levels and is not exclusively
dependent on HIF1 (reviewed by Xie et al, 2004). A thioredoxin
inhibitor such as AW464 is most likely to inhibit the HIF1 and its
associated signalling pathways (e.g. PI3K and Ras pathways) and
future assays (macro/microarrays, transactivation assays and
Westerns) have been contemplated to further characterise the
inhibition at the molecular level.
The efficacy of low doses of AW464 in decreasing proliferation
under hypoxic conditions and also decreasing VEGF levels may be
utilised by low-dose scheduling of the drug. Recent studies have
shown that frequent administration in vivo of low doses of
chemotherapeutic drugs (‘metronomic’ dosing) can affect tumour
endothelium and inhibit tumour angiogenesis, reducing significant
side effects (e.g., myelosuppression) (Browder et al, 2000; Gately
and Kerbel, 2001; Bocci et al, 2002). VEGF is not only a
proangiogenic factor but can also cause drug/radiation resistance,
inhibit apoptosis, impair drug delivery and act as a tumour cell
survival factor (reviewed by Harmey and Bouchier-Hayes, 2002).
Therefore, lower doses of AW464 that inhibit VEGF, may abrogate
all these harmful effects in addition to indirectly preventing
angiogenesis. Targeting VEGF may be an important therapeutic
tool in colorectal cancer as shown by recent phase II clinical trial
results with bevacizumab, a recombinant monoclonal antibody to
VEGF (Kabbinavar et al, 2003). Time to progression was longer in
patients receiving bevacizumab and 5FU-leucovorin than those
receiving 5-FU leucovorin alone (9.2 vs 5.2 months) (Berlin, 2002).
Thus AW464, with its chemotherapeutic and antiangiogenic
potential, may be a worthwhile drug for colorectal cancer therapy.
Since the subtoxic doses of the drug are most effective in
decreasing proliferation under hypoxic conditions and in reducing
VEGF levels, it will probably be used as combination therapy
without itself causing serious side effects.
From current results, we conclude that AW464, a novel
thioredoxin inhibitor, is an effective drug in vitro against tumour
cells. The added advantage is that its effects may be potentiated
under hypoxic conditions at low doses. Fibroblasts are relatively
resistant to AW464 and hence some normal tissues may be
differentially spared. Potential antiangiogenic effects of the drug
are evident in its specificity for proliferating endothelial cells,
inhibition of endothelial tube differentiation and reduction in
VEGF levels at low doses. bFGF is however unaffected and hence
HIF1a inhibition is now being investigated. The drug warrants
further experimentation, especially in vivo, to prove its antitumour
and antiangiogenic effects. While in vitro results may not always
correlate with in vivo effects, initial characterisation of novel
agents is often conducted in appropriate in vitro models. For
example, the NCI screen for antiangiogenic agents uses in vitro
proliferation, tube differentiation on Matrigel and chemotaxis
assays in Boyden chambers; a compound positive for effects on
any one of these assays is carried forward for in vivo analysis.
Some preliminary studies for antitumour effects have been
conducted with human renal cell carcinoma RXF 944XL hyperne-
phroma xenografts in nude mice (Wells et al, 2003). Treatment
with AW464 15mgkg
1 on day 1 and day 8 produced 57% growth
retardation; treatments on day 1 and 2 produced a growth
inhibition of 73%. In HT29 colon xenograft studies, 14 days post-
treatment with AW464, there was a tumour growth delay of 7 days
accompanied by 42.5% growth inhibition. Further assays are
currently being conducted to validate thioredoxin as the
potential drug target and elucidate whether HIF1a may be
inhibited as a consequence. Thioredoxin motifs are also present
in molecules such as the protein disulphide isomerases
and the endothelial specific PDIs. Whereas PDIs protect endothe-
lial cells during both normoxia and hypoxia, EndoPDIs are
upregulated and protect during hypoxic stress (Sullivan et al,
2003). Future investigations of potential antiangiogenic
mechanisms may involve effects of AW464 on these redox active
molecules. Thioredoxin as a molecular target is upstream of
several regulatory processes key to the survival of tumours. A
potential thioredoxin inhibitor such as AW464 that targets both
the tumour and endothelial cell represents an effective therapy for
colorectal cancer.
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